{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "binds",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ06262",
      "entity_text" : "interleukin-6 receptors",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ06271",
      "entity_text" : "mAb",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:9606" ],
      "Cellular_component" : [ "go:GO:0016020" ]
    }
  },
  "verbose_text" : "Sarilumab is a human immunoglobulin G1 monoclonal antibody (mAb) that binds specifically to both soluble and membrane bound interleukin-6 receptors (IL-6Rs) and has been shown to inhibit IL-6-mediated signaling through these receptors.",
  "reading_complete" : "2020-07-28T15:31:08Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T15:25:59Z",
  "trigger" : "binds",
  "evidence" : [ "mAb) that binds specifically to both soluble and membrane-bound interleukin-6 receptors" ],
  "pmc_id" : "6702535",
  "score" : 0
}